Latest Product Pipeline News

Mesoblast Limited has reported its FY2025 results, highlighting the FDA approval and US commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, alongside a $102.1 million net loss and $161.6 million in cash reserves.

Tetratherix Limited advances its Tetramatrix biomaterial platform with a robust IP portfolio, scalable manufacturing, and strategic partnerships aimed at commercialising across multiple clinical franchises.

Tetratherix Limited reports its first financial results as a listed company, revealing a $9.4 million statutory loss driven by R&D and listing costs, alongside a robust $29.3 million cash position post-IPO. The company highlights key operational milestones and outlines strategic plans to accelerate commercialisation across its innovative biomaterial platform.

Tetratherix Limited reported a $9.4 million statutory loss for FY25 amid significant R&D and operational investments, successfully listing on the ASX and progressing multiple clinical and manufacturing initiatives.

Qoria Limited reported a robust FY2025 with 25% growth in annual recurring revenue and a 684% jump in EBITDA, underscoring its expanding leadership in global K12 safety and wellbeing platforms.

AnteoTech Ltd reported a 110% revenue increase to A$968,878 in FY2025 alongside a 24% reduction in net loss, driven by strategic cost savings and key partnerships. Leadership renewal and product validation position the company for growth in battery and life sciences markets.

Terragen Holdings reported a $3.72 million loss for FY25, impacted by drought and lower revenues, while launching dry probiotic products targeting feedlots and completing a $4.76 million equity raise.

CleanSpace Holdings Limited reported a 26% increase in revenue to $19.8 million for FY25, alongside a significant reduction in net loss to $478,276. The company’s strategic expansion and innovation efforts underpin its improving financial health and global market presence.

Firebrick Pharma has closed a $1.4 million placement to fund expansion of its Nasodine nasal spray in key international markets and advance new product development.

Imricor Medical Systems reported a sharp 52% revenue decline and a 92% increase in net loss for H1 2025, offset by a $42.8 million equity raise boosting liquidity. The company is investing heavily in European sales and clinical trials while pursuing FDA approval.

Codan Limited reported a robust FY25 with revenue climbing 22% to $674.2 million and net profit rising 27%, driven by strong performances in its Communications and Metal Detection segments.

Codan Limited has delivered a robust FY25 performance, with revenue up 22% and net profit rising 27%, underpinned by strong growth in its Communications and Metal Detection segments. The company also announced a 27% increase in dividends and a significant reduction in net debt.